Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients
The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients. This study was conducted to identify optimal regimens of BLBLIs in these patients. A Monte Carlo simulati...
Main Authors: | Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong, Taotao Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/10/8/993 |
Similar Items
-
Comparative Evaluation of the in-vitro Activity of Six β-lactam/β-lactamase Inhibitor Combinations against Gram Negative Bacilli
by: Smita Sood
Published: (2013-02-01) -
Effect of β-Lactamase inhibitors on in vitro activity of β-Lactam antibiotics against Burkholderia cepacia complex species
by: Annelien Everaert, et al.
Published: (2016-11-01) -
β-Lactam Antibiotics Renaissance
by: Wenling Qin, et al.
Published: (2014-05-01) -
Antimicrobial susceptibility to β-lactam antibiotics and production of BRO β-lactamase in clinical isolates of Moraxella catarrhalis from a Japanese hospital
by: Kageto Yamada, et al.
Published: (2017-06-01) -
Could β-Lactam Antibiotics Block Humoral Immunity?
by: Cléa Melenotte, et al.
Published: (2021-09-01)